登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Her2 >HE2-H5225

Human Her2 / ErbB2 Protein, His Tag (MALS verified)

分子别名(Synonym)

ERBB2,CD340,HER-2,neu,HER2,MLN19,NEU,NGL,TKR1

表达区间及表达系统(Source)

Human Her2, His Tag (HE2-H5225) is expressed from human 293 cells (HEK293). It contains AA Thr 23 - Thr 652 (Accession # P04626-1).

Predicted N-terminus: Thr 23

Request for sequence

蛋白结构(Molecular Characterization)

Her2 Structure

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 70.2 kDa. The protein migrates as 70-95 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 0.2 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Her2 SDS-PAGE

Human Her2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

Her2 SEC-MALS

The purity of Human Her2, His Tag (Cat. No. HE2-H5225) is more than 90% and the molecular weight of this protein is around 75-105 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

Her2 ELISA

Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL (100 μL/well) can bind Anti-Her2 antibody with a linear range of 0.061-1.95 ng/mL (QC tested).

Protocol

Her2 ELISA

Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL (100 μL/well) can bind Pertuzumab Biosimilar with a linear range of 0.2-4 ng/mL (Routinely tested).

Protocol

Her2 ELISA

Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL (100 μL/well) can bind Trastuzumab Biosimilar with a linear range of 0.1-2 ng/mL (Routinely tested).

Protocol

Her2 ELISA

Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL (100 μL/well) can bind Bispecific Antibody (Her2 × Her3) with a linear range of 0.8-3 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-SPR

Her2 SPR

Herceptin (Trastuzumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

Her2 BLI

Loaded Herceptin (Trastuzumab) on AHC Biosensor, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 0.825 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 
评论(42)
  1. 187XXXXXXX2
  2. 20人赞
  3. 该hHer-2 蛋白活性好,包被浓度很低就可以进行ELISA检测,使用量少,同时也节省了成本。另外也购买了另一款抗体,活性也不错,服务态度也好
  4. 2019-10-12
  1. 183XXXXXXX6
  2. 2人赞
  3. 这个抗原用来检测抗体亲和力,抗原带his标签,抗体带fc标签,所以可以捕获抗体,流动抗原,最后得到的亲和力和文献以及预期差不多,-9左右。
  4. >
  5. 2022-5-27
  1. 131XXXXXXX6
  2. 2人赞
  3. 主要用于抗体结合的性能确认,用于ELISA试验,结合灵敏,曲线完美,并且包被浓度也比较低,总的来说本抗原性能不错,满足实验要求。服务也不错,下次其他项目也会考虑
  4. 2022-12-21
 
ACRO质量管理体系
 
 

背景(Background)

Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation .

文献引用(Citations)

 

前沿进展

Real-World Molecular Testing Rates and Patterns in Patients With Primary Advanced or Recurrent Endometrial Cancer in the United States
Chen, Lubinga, Williams et al
JCO Precis Oncol (2025) 9, e2400815
Abstract: This retrospective cohort study estimated the real-world utilization of biomarker testing among patients with primary advanced/recurrent endometrial cancer (pA/rEC) and characterized testing according to demographic and clinical characteristics.A nationwide electronic health record-derived deidentified database was used. Records from January 1, 2013, to August 31, 2023, for women age 18 years and older with pA/rEC were searched for DNA mismatch repair (MMR)/microsatellite instability (MSI), human epidermal growth factor receptor 2 (HER2), and estrogen receptor (ER) or progesterone receptor (PR) testing; a subsample data set (advEndo Spotlight) was searched from April 1, 2013, to November 30, 2022, for additional biomolecular testing. Testing rates were reported by index year and molecular marker. Multivariate logistic regression analyses were conducted to identify characteristics associated with testing.The full data set included 2,982 patients, of whom 53% were age 65 years and older; most were non-Hispanic White (56%) and received care in a community setting (73%). The advEndo Spotlight subsample (n = 509) had similar characteristics. From 2013 to 2021, testing for any biomarker increased from 53% to 89% (MMR/MSI, 17% to 81%; ER/PR, 45% to 62%; HER2, 15% to 43%). Patients who received care at an academic versus community facility, had commercial/other insurance versus Medicare/Medicaid, had primary advanced versus recurrent EC, had endometrioid versus nonendometrioid carcinoma, or had no previous surgery as part of primary treatment were more likely to receive testing.Molecular testing rates in pA/rEC have increased over time, likely due in part to incorporation of biomarker testing into treatment guidelines. This highlights an unmet need to ensure universal access to testing in patients with pA/rEC. Understanding these factors can inform approaches to increase access to molecular testing and increase testing rates.
Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial
Kuerer, Valero, Smith et al
JAMA Oncol (2025)
Abstract: Neoadjuvant systemic therapy (NST) has been associated with pathologic complete response (pCR) in up to 60% of breast cancers (BCs). The findings of this trial question the necessity of surgery.To report preplanned 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients selected with image-guided vacuum assisted biopsy (VAB).This single-arm, prospective, phase 2 nonrandomized clinical trial was conducted at 7 US medical centers and included women 40 years or older with cT1-2N0-1M0 ERBB2-positive (formerly HER2-positive) or triple-negative invasive BC who showed residual breast lesions after NST of less than 2 cm on imaging. Enrollment was from March 6, 2017, to November 9, 2021. Data analysis was from October to December 2024.Image-guided VAB of the tumor bed (9G with a minimum of 12 cores) was performed after standard NST. Patients with clinically node-negative disease at diagnosis and no residual cancer in the breast on post-NST VAB underwent whole-breast radiotherapy with a boost without breast or axillary surgery. Patients with initial documented nodal disease and a breast pCR on VAB underwent targeted axillary dissection, while those with residual cancer when undergoing VAB had standard breast and axillary surgery. Patients were monitored with physical examinations and mammography every 6 months.The primary outcome was ipsilateral breast tumor recurrence.Fifty patients (median [IQR] age, 62 [55-77] years) were enrolled and underwent post-NST VAB. Twenty-nine (58%) and 21 (42%) patients had ERBB2-positive and triple-negative invasive BC, respectively. Breast pCR on VAB was identified in 31 patients (62%; 95% CI, 47.2%-75.34%), and axillary pCR was identified among all 8 patients with initial nodal metastases and breast pCR on VAB who underwent targeted axillary dissection. At a median follow-up of 55.4 (IQR, 44.0-63.5) months, the ipsilateral breast tumor recurrence rate was 0%, and disease-free and overall survival rates were 100% for patients without breast surgery.The results of this nonrandomized clinical trial that reported preplanned 5-year outcomes suggest that omission of breast surgery in select patients after NST may be feasible, with no recurrences seen. More confirmatory studies are necessary before this new approach alters surgical practice.ClinicalTrials.gov Identifier: NCT02945579.
NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate
Chazeau, Pipier, Wegner et al
J Med Chem (2025)
Abstract: Real-time imaging of antibody-drug conjugates (ADCs) offers valuable insights for assessing tumor targeting specificity, monitoring therapeutic efficacy, and detecting off-target accumulation that may cause adverse effects. To enable precise tracking, we developed a versatile fluorescent platform based on an NIR-II emitting aza-BODIPY dye, which can be site-specifically grafted onto an IgG1 antibody to generate well-defined fluorescent ADCs. As a proof of concept, we synthesized an HER2-targeting trastuzumab immunoconjugate bearing a NIR-II aza-BODIPY fluorophore. The cytotoxic monomethyl auristatin E (MMAE) payload was introduced in the final step, resulting in a trackable and homogeneous ADC suitable for both in vitro and in vivo investigations. The resulting Trastu-azaNIRII-MMAE selectively accumulated in HER2-positive subcutaneous tumors, significantly reducing the tumor growth. Using NIR-II optical imaging, a single injection of the NIR-II-ADC allowed for the detection of the conjugate over a period of more than one month, highlighting its potential for long-term tracking and therapeutic applications.
Dynamics of hyperglycemia of patients treated with alpelisib: exploratory interim analysis of ITACA trial
Pancirov, Flam, Šuto Pavičić et al
Oncologist (2025) 30 (3)
Abstract: Alpelisib and fulvestrant combination has improved outcomes in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-)- advanced breast cancer (BC) who relapsed or progressed on prior endocrine therapy. Hyperglycemia, on target toxicity, is a frequent adverse event occurring in over 60% of patients.The ITACA trial explores whether low carbohydrate dietary modifications and evening dosing of alpelisib to potentially mitigate impact of food on hyperglycemia. This exploratory interim analysis aimed to quantify the incidence and timing of hyperglycemia in the ITACA trial's pooled sample.This exploratory interim analysis of the ongoing ITACA trial included 23 patients with HR+, HER2-negative metastatic BC receiving alpelisib and fulvestrant. The exploratory outcomes were grade 2-4 hyperglycemia-free survival and time to onset of hyperglycemia.Most patients, 21 (91.3%), experienced any-grade hyperglycemia (Grade 1: 9 [39.1%], Grade 2: 8 [34.8%], Grade 3: 4 [17.4%], and Grade 4: 0 [0.0%]) within the first week of alpelisib initiation. The median grade 2-4 hyperglycemia-free survival was 6 days (95% CI 3; 44 days).This exploratory interim analysis demonstrated the rapid onset of hyperglycemia in patients receiving alpelisib, even with the ITACA trial's dietary interventions. Proactive monitoring, within the first week after initiation of treatment, and early management of hyperglycemia are crucial in this patient population.© The Author(s) 2025. Published by Oxford University Press.
Showing 1-4 of 46285 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Her2靶点信息
英文全称:Receptor protein-tyrosine kinase erbB-2
中文全称:受体蛋白酪氨酸激酶 erbB-2
种类:Homo sapiens
上市药物数量:39详情
临床药物数量:201详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定